

Clinical efficacy and safety of spironolactone in patients with resistant hypertension

A systematic review and meta-analysis

Cong Chen, PhD^a, Xue-Ying Zhu, MD^b, Dong Li, PhD^c, Qian Lin, PhD^{a,*}, Kun Zhou, PhD^{c,*}

Abstract

Background: We conducted a meta-analysis to summarize all available evidence from randomized controlled trial studies regarding the clinical efficacy and safety of spironolactone in patients with resistant hypertension (RH) and provided a quantitative assessment.

Methods: A systematic search of PubMed, Web of Science, Cochrane Library, Embase, and China National Knowledge Infrastructure (CNKI) databases through December 8, 2019, was performed. Randomized controlled trials randomized controlled trials meeting inclusion criteria were included to assess the effect of the addition of spironolactone on office blood pressure (BP), 24-hour ambulatory BP or adverse events in RH patients.

Results: Twelve trials, which enrolled a total of 1655 patients, were included in this meta-analysis. In comparison with placebo, spironolactone significantly reduced office BP (office SBP, weighted mean difference [WMD] = -20.14, 95% CI = -31.17 to -9.12, P < .001; office DBP WMD = -5.73, 95% CI = -8.13 to -3.33, P < .001) and 24-hour ambulatory BP (ASBP, WMD = -10.31, 95% CI = -12.86 to -7.76, P < .001; ADBP, WMD = -3.94, 95% CI = -5.50 to -2.37, P < .001). Compared with alternative drugs, spironolactone treatment in RH patients significantly decreased 24-hour ambulatory BP (ASBP, WMD = -6.98, 95% CI = -12.66 to -1.30, P < .05; ADBP, WMD = -3.03, 95% CI = -5.21 to -0.85, P < .001).

Conclusion: This meta-analysis fully evaluated the antihypertensive effect of spironolactone compared with placebo, alternative drugs, renal nerve denervation and no treatment. Spironolactone can result in a substantial BP reduction in patients with RH at 3 months.

Abbreviations: BP = blood pressure, CI = confidence interval, CKD = chronic kidney disease, RCT = randomized controlled trial, RH = resistant hypertension, WMD = weighted mean difference.

Keywords: meta-analysis, resistant hypertension, spironolactone

1. Introduction

Patients with hypertension are at higher the risk of cardiovascular disease and stroke.^[1] Although many antihypertensive drug

Editor: Leonardo Roever.

CC and X-YZ are co-first authors.

This work was supported by the National Natural Science Foundation of China (No. 81874385/81673758).

The authors have no conflicts of interest to disclose.

The datasets generated during and/or analyzed during the current study are publicly available.

^a Dongzhimen Hospital Beijing University of Chinese Medicine, Beijing, ^b Shandong University of Traditional Chinese Medicine, ^c Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, China.

* Correspondence: Qian Lin, Dongzhimen Hospital Beijing University of Chinese Medicine, Beijing 100700, China; Kun Zhou, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing 100078, China (e-mail: Alinqian62@126.com, dfzhk@126.com).

Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Chen C, Zhu XY, Li D, Lin Q, Zhou K. Clinical efficacy and safety of spironolactone in patients with resistant hypertension: a systematic review and meta-analysis. Medicine 2020;99:34(e21694).

Received: 3 March 2020 / Received in final form: 1 July 2020 / Accepted: 6 July 2020

http://dx.doi.org/10.1097/MD.00000000021694

options are available, the blood pressure (BP) targets for individuals with suboptimal BP are hard to achieve. The inability to reach standard BP levels (below 140/90 mm Hg) despite the concurrent use of 3 or more antihypertensive agents of different classes that include at least one kind of diuretic is defined as resistant hypertension (RH). The etiology of RH is poorly understood, but it is associated with diabetes, chronic kidney disease (CKD), and obesity.^[2] To improve BP control in patients with RH, lifestyle modification should be recommended. Despite the ineffectiveness of the first 3 recommended drugs, including calcium channel blockers (CCBs), angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEIs/ARBs), and thiazide diuretics,^[3] adherence should be carefully assessed to exclude pseudo resistance. New treatment strategies must be developed to improve BP control.

Currently, the most suitable fourth drug to add to the 3 commonly prescribed antihypertension drugs is not well established.^[4,5] However, some recent observational studies have demonstrated that the addition of spironolactone to tripledrug therapy was the most effective add-on drug for patients with RH.^[6] As a mineralocorticoid receptor antagonist, spironolactone has a promising effect on lowering BP in hypertensive patients.^[7] The adverse effects of spironolactone, including gynecomastia, breast discomfort, and biochemical abnormalities, are relatively.^[6] Although some randomized controlled trials (RCTs) have demonstrated the efficacy of spironolactone as a fourth-line therapy for patients with RH, there are no available high-quality, large-scale clinical trials to evaluate the efficacy and safety of spironolactone for RH.^[8]

We conducted a meta-analysis to summarize all available evidence from RCT studies regarding the clinical efficacy and safety of spironolactone in patients with RH, and we conducted a quantitative assessment. The results of this study were merged with updated available evidence to fully assess the influence of spironolactone on BP compared with placebo and other active interventions. To our knowledge, this was the first study that included data describing BP changes over time.

2. Methods

This meta-analysis was performed, according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)^[9] guidelines, to elaborate the effect of spironolactone on RH.

2.1. Data source and search strategy

Two reviewers systematically searched 5 electronic databases, including PubMed, the Web of Science, the Cochrane Library, Embase, and China National Knowledge Infrastructure (CNKI), until December 8, 2019. The search terms were "spironolactone" and "resistant hypertension" matched with "Randomized Controlled Trial" or "Clinical Trial" OR "Controlled Clinical Trial." The language was not limited. Our meta-analysis selected only the most recent publication when the same study had been published in different journals or in different years. If different studies were selected for the meta-analysis.

2.2. Selection criteria

Two reviewers independently examined the titles and abstracts of all obtained articles. Eligible studies met the following inclusion criteria:

- (1) RCT design;
- (2) patients with RH (the use of at least 3 antihypertensive drugs from 3 different classes did not achieve a standard BP goal);
- (3) office, home or ambulatory BP monitoring;
- (4) a follow-up of at least 4 weeks; and
- (5) a clear description of relevant outcomes.

Articles that were not RCTs, including letters, practice guidelines, conference theses, commentaries, and editorials, were excluded, but relevant articles from the reference lists were retrieved to identify potential studies.

2.3. Data collection and quality assessment

Relevant data were collected independently by 2 reviewers, and the third reviewer was responsible for resolving discrepancies through discussion. The standardized predefined form used included 4 parts:

- (1) basic information: title, first author, the year of publication, and corresponding address;
- (2) study characteristics: the type of intervention and control, daily dosage of intervention, study design, inclusion and exclusion criteria, and RH definition;
- (3) the characteristics of participants: sample size, sex distribution, mean age and race; and

(4) results of the study: outcome measures of BP and heart rate. When there were missing data, errors or ambiguous information in the included studies, we contacted the original authors of the study. If the author failed to answer the questions, insufficient information was neglected, or the study was excluded. Different opinions between reviewers were resolved by communication with other reviewers.

We assessed the quality of the involved RCTs by using the Cochrane Collaboration tool. Two reviewers who performed data extraction separately evaluated the risk of bias in the involved studies. Disagreements in scoring were resolved by discussion among the reviewers. Several sources of bias are evaluated in the Cochrane Collaboration tool, including random sequence generation; allocation concealment; the blinding of participants, personnel, and outcome assessment; incomplete outcome data; selective reporting; and anything else, ideally prespecified, and others.

2.4. Data synthesis and statistical analysis

All statistical analyses were performed using Cochrane Program Review Manager Version 5.3 (Cochrane Collaboration, Oxford, UK). We used the I2 test and chi-squared test to evaluate the heterogeneity of the included RCTs to estimate the discrepancy across studies (when I2 values <50% and P > .10, there was no obvious heterogeneity). A random-effects model was utilized when heterogeneity was obvious; otherwise, a fixed-effects model was used. The risk ratio and weighted mean difference (WMD) were used to represent binary variables and continuous variables, respectively, with a 95% confidence interval (CI). A funnel plot was used to detect publication bias and meta-regression analysis was used to evaluate the factor of effect on heterogeneity.

2.5. Grading the quality of evidence

The quality of evidence for outcomes will be evaluated using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE). In the GRADE system, the quality of evidence will be classified into very low, low, moderate, or high judgment.

2.6. Ethics


Ethical approval was not required.

3. Result

3.1. Literature selection and study characteristics

Overall, 1988 studies were identified by searching databases (296 from PubMed, 1058 from Embase, 474 from the Web of Science, 158 from the Cochrane Library, and 2 from CNKI). After removing duplicates, 1208 remained and were evaluated. By assessing abstracts and full texts, 77 studies were eligible and then further examined thoroughly. Finally, 12 studies met our inclusion criteria, and 65 were excluded for the following reasons: 35 were not RCTs, 23 had incomplete data, and 7 were the same studies at different stages. The literature search processing and reasons for exclusion are listed in Figure 1.

The main characteristics of the included RCTs are listed in Table 1. The major baseline characteristics of each study's spironolactone group and placebo or active control group were similar. We systematically analyzed 12 RCTs, encompassing



1655 patients. There were four RCTs^[10–13] that selected patients with CKD, heart failure and obstructive sleep apnea and those on dialysis. Two RCTs^[14,15] enrolled participants with type 2 diabetes mellitus and 2 RCTs^[16,17] were conducted in patients with true RH.

3.2. Quality assessment

According to the Cochrane risk of bias tool, most items of the included studies are given in Figures 2 and 3. In these included RCTs, 5 studies^[12,16–19] were open label and did not provide clear information on the accurate assessment of the risk of bias; therefore, they were evaluated as having an unclear risk of bias.

The details for the blinding of outcome assessment in 1 study were inaccessible; therefore, the study was evaluated as having a high risk of bias.^[14] The results of the quality evaluation of the eligible RCTs are shown in Figures 2 and 3.

3.3. SBP

In this meta-analysis, we used a random-effects model to analyze the outcomes. In comparison with placebo, spironolactone significantly reduced office SBP in patients with RH (WMD = -20.14, 95% CI = -31.17 to -9.12, P < .001). Compared with no treatment, spironolactone also significantly reduced SBP (WMD = -9, 95% CI = -16.85 to -1.15). However, there was

Table 1 Characteristics of included studies

Author/yr	Country	Design	Center	Sample Size	Mean age (yr)	Male, %	Mean dose of SPI (mg/d)	Duration, wk	Control group	Efficacy outcomes	Safety outcome
Bobrie et al, 2012	France	RCT	Single	167	SPI: 56.7 Control: 55	75.4	25	12	Ramipril	Daytime ABP Night- time ABP 24-hr ABP Office BP	None
Abolghasmi et al, 2011	Iran	RCT	Single	41	SPI: 49 Control: 50	44.9	25–50	12	Placebo	Office BP	Serum potassium
Ni et al, 2014	China	RCT	Two	76	SPI: 55.7 Control: 54.9	59.2	25	12	Placebo	24-hr ABP Office BP	Serum potassium
Oxlund et al, 2013	Denmark	RCT	Single	119	SPI: 62.9 Control: 63.9	76.5	25	16	Placebo	Daytime ABP Night- time ABP 24-hr ABP Office BP	Serum potassium
Václavik et al, 2014	Czech	RCT	Multicenter	150	SPI: 60.4 Control: 59.7	65.3	25	8	Placebo	Daytime ABP Night- time ABP 24-hr ABP Office BP	Serum potassium
Williams et al, 2015	United Kingdom	RCT	Multicenter	335	61.4	68.7	25–50	12	Placebo, bisoprolol (5–10 mg) and dox- azosin (4–8 mg)	Office BP	Serum potassium
Djoumessi et al, 2016	Cameroon	RCT	Single	17	62.9	47.1	25	4	Candesartan (8 mg), atenolol (100 mg), or alpha methyldopa (750 mg)	Office BP	Serum potassium
Oliveras et al, 2016	Spain	RCT	Multicenter	24	SPI: 64.9 RNd: 61.9	62.5	50	24	RDN	Daytime ABP Night- time ABP 24-hr ABP Office BP	Serum potassium
Rossignol et al, 2018	international	RCT	Multicenter	403	SPI: 85 Control: 75	39.5	23	32	Placebo	Office BP	Serum potassium
Rosa et al, 2016	Czech	RCT	Multicenter	106	SPI: 59 RNd:56	69.8	25	48	RDN	24-hr ABP Office BP	Serum potassium
Yang et al, 2016	china'	RCT	Single	30	SPI: 15 RNd: 15	None	20-40	12	Blank	Daytime ABP Night- time ABP 24-hr ABP Office BP	Serum potassium
Krieger et al, 2018	Brazil	RCT	Multicenter	187	55	45.5	12.5–50	12	Clonidine	Daytime ABP Night- time ABP 24-hr ABP Office BP	Serum potassium

RCT, randomized controlled trial, RDN = renal denervation

no significant difference between spironolactone and alternative drugs or renal nerve denervation (RND) in the effect on office SBP. Relatively high heterogeneity was shown in comparison with the placebo group, which might be related to the background therapy, the dose of spironolactone, the duration of the intervention and demographic characteristics in each study. (Fig. 4)

Compared with placebo and no treatment, spironolactone significantly reduced the 24-hour ambulatory SBP (WMD=-10.31, 95% CI=-12.86 to -7.76, P < .001) (WMD=-11.00, 95% CI=-19.25 to -2.75). There was no significant difference between spironolactone and RND in the reduction in 24-hour ambulatory SBP. However, in comparison with alternative drugs, spironolactone showed a significant difference in the reduction in 24-hour ambulatory SBP (WMD=-6.98, 95% CI=-12.66 to -1.30, P < .05), with relatively obvious heterogeneity (Fig. 5).




Figure 2. Risk of bias graph.


3.4. DBP

For the changes in DBP from baseline to study endpoint, we performed a random-effects model to analyze the outcomes. Compared with the placebo group, spironolactone significantly decreased office DBP (WMD=-5.73,95% CI=-8.13 to -3.33, P < .001). Apart from comparison with the placebo group, the data analysis did not show any significant difference between spironolactone and the other control groups. Significant heterogeneity was present between spironolactone and placebo because of the dose of spironolactone, the duration of intervention and demographic characteristics (Fig. 6).

Spironolactone still significantly reduced 24-hour ambulatory DBP compared with placebo (WMD = -3.94, 95% CI = -5.50 to -2.37, P < .001) and blank groups (WMD = -12, 95% CI = -16.77 to -7.23). There was no significant difference between spironolactone and RND in the reduction in 24-hour ambulatory DBP. However, in comparison with alternative drugs, spironolactone showed a significant difference in the reduction in 24-hour ambulatory DBP (WMD=-3.03, 95% CI=-5.21 to -0.85, P < .001) without heterogeneity (Fig. 7).

3.5. The duration of intervention

In addition, we performed subgroup analysis according to the duration of intervention. In comparison with placebo, the effect of 3 months of spironolactone (WMD=-29.88, 95% CI=-41.13 to -18.64, P < .001) was better than that of less than 3 months (WMD=-20.4, 95% CI=-41.08 to -0.27, P=.05) or longer than 3 months on SBP (WMD=-8.62, 95% CI=-14.23 to -3.01, P < .05). (Fig. 8) Subgroup analysis showed that the





effect of 3 months of spironolactone (WMD=-7.26, 95% CI=-11.7 to -2.81, P < .001) was better than that of less than 3 months (WMD=-6.62, 95% CI=-13.48 to 0.24, P=.06) or longer than 3 months on DBP (WMD=-3.95, 95% CI=-6.59 to -1.32, P < .05) (Fig. 9).

3.6. Safety outcomes

The mean change in serum potassium was defined as the safety outcome, and data were collected from baseline to study endpoint to evaluate whether spironolactone increased the risk of hyperkalemia in patients with RH. Compared to the placebo, spironolactone indeed elevated serum potassium levels (WMD = 0.2, 95% CI=0.05 to 0.35, P < .01) without heterogeneity. However, the spironolactone group did not show any increased risk of elevated serum potassium levels compared with the other-treatment control groups, such as those who received alternative drugs, no treatment, or RND (Fig. 10).

3.7. Publication bias

A forest plot of the comparison of spironolactone vs placebo, alternative drugs, RND and no treatment for the outcome of 24hour ambulatory SBP is shown in Figure 11.

3.8. Meta-regression analysis for heterogeneity

The following specific variables were separately evaluated for their effects on heterogeneity: country, year, sample size. Metaregression showed that these variables did not explain heterogeneity observed for specificity (Table 2).

3.9. The quality of the evidence

The quality assessment of evidence for office BP and ambulatory BP is presented in Tables 3 and 4 using GRADE system.

4. Discussion

The objective of this meta-analysis was to evaluate and quantify the effect of spironolactone on BP in patients with RH. Although the underlying mechanism of RH is unclear, there is numerous evidence that resistant HTN is generally volume-dependent, attributable to differing levels of aldosterone excess with its attendant renal effects on sodium and fluid retention. Such aldosteronism most commonly exists separately from and independent of angiotensin II.^[20] The aldosterone-induced volume excess is placed at the root of the development of RH in a large number of patients, with primary aldosteronism being present in approximately 20% of patients.^[21] Some studies reported that aldosterone could predict new hypertension, type 2 diabetes mellitus, central obesity, and the use of lipid-lowering drugs in the general community and remained associated with hypertension, obesity, and CKD over 4 years.^[22] The administration of spironolactone, a mineralocorticoid receptor antagonist, as a fourth-line agent significantly decreased office BP and 24-hour ambulatory BP compared with placebo based on the results of our meta-analysis. A previous study showed that the add-on use of spironolactone in patients with RH compared with placebo was effective in lowering SBP and DBP.^[23] Our subgroup meta-analysis further showed that 3 months of intervention with spironolactone could reduce SBP significantly compared with placebo but that the degrees of reduction would decrease when the intervention was less than 3 months or more than 3 months. This finding that a 3-month duration of intervention with spironolactone had the best effect was newly discovered through our meta-analysis, but the specific mechanism is not clear. Our later research will further explore the underlying mechanism.

This meta-analysis included 4 RCTs (with 916 patients) that evaluated the effectiveness of spironolactone (12.5–50 mg/d) on RH with a control treatment—ramipril in 1 trial, bisoprolol in 1 trial, clonidine in 1 trial and an alternative treatment (candesartan, atenolol, or alpha methyldopa) in 1 trial. The follow-up periods ranged from 8 to 12 weeks. Although there were no significant differences in the effects of spironolactone vs alternative drugs on office SBP and DBP, the results of 24-hour ambulatory BP still demonstrated that spironolactone had a better antihypertensive effect. ABPM has the advantage of less bias than office BP and provides a complete picture of BP values throughout the day. Some studies have supported the concept that ABPM is less vulnerable to other factors effects since it is assessed in a patient's daily life.^[24] The area under the curve of the ABPM is more accurate than that of office BP taken at fixed

	Spire	onolactor	1e	p	lacebo			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl
1.1.1 compared with plac	ebo								
Abolghasmi et al., 2011	-36	10	19	5	10	22	7.9%	-41.00 [-47.14, -34.86]	-
Ni et al., 2014	-20	11.63	40	-3	15.4	36	7.9%	-17.00 [-23.19, -10.81]	
Oxlund et al., 2013	-10.5	15.618	61	5.3	17.4	58	7.9%	-15.80 [-21.75, -9.85]	
Rossignol P et al. 2018	-15.65	19.47	164	-9.82	19.52	174	8.1%	-5.83 [-9.99, -1.67]	
Václavik et al., 2014	-17.6	15.5	74	-7.7	14.4	76	8.1%	-9.90 [-14.69, -5.11]	
Williams et al., 2015	-20.7	18.5	285	10.8	18.2	274	8.2%	-31.50 [-34.54, -28.46]	-
Subtotal (95% CI)			643			640	48.2%	-20.14 [-31.17, -9.12]	•
Heterogeneity: Tau ² = 182	.92; Chi ²	= 162.78	, df = 5	(P < 0.0	00001);1	2= 979	16		
Test for overall effect: Z = 3	3.58 (P =	0.0003)							
1.1.2 compared with alter	rnative d	ruas							
Bobrie et al., 2012	-22	19	85	-11	22.2	82	7.9%	-11.00 [-17.28, -4.72]	
Dioumessi et al. 2016	-33	14.9	9	-14	14.7	8	6.5%	-19.00 [-33.09, -4.91]	
Krieger EM et al. 2018	-40	17.76	84		18,76	78	8.0%	3.10 [-2.54, 8.74]	
Williams et al., 2015	-20.7	18.5	285	-16.3	18.5	285	8.2%	-4.40 [-7.44, -1.36]	
Subtotal (95% CI)		10.0	463		10.0	453		-6.08 [-12.83, 0.68]	•
Heterogeneity: Tau ² = 34.6	62: Chi ² =	15.18 d	f = 3 (P	= 0.002): I ² = 80	0%			
Test for overall effect: Z =									
1.1.3 compared with RDN	í								
Oliveras A et al. 2016	-29.4	20,79	13	-17.5	20.81	11	6.0%	-11.90 [-28.60, 4.80]	
Rosa J et al. 2016	-11.3	20.4	50		19.55	51	7.7%	2.10 [-5.69, 9.89]	
Subtotal (95% CI)		20.1	63			62	13.6%	-2.87 [-16.00, 10.26]	-
Heterogeneity: Tau ² = 53.1	78: Chi ² =	2.22 df:	= 1 (P =	= 0 14):	P = 55%				
Test for overall effect: Z = I									
1.1.4 comapred with blan	k group								
Yang L et al. 2016	-19.9	12.7	15	-10.9	8.9	15	7.7%	-9.00 [-16.85, -1.15]	
Subtotal (95% CI)			15			15	7.7%	-9.00 [-16.85, -1.15]	•
Heterogeneity: Not applica	able								
Test for overall effect: Z = :		0.02)							
Total (95% CI)			1184				100.0%	-13.15 [-20.79, -5.51]	•
Heterogeneity: Tau ² = 182			, df = 1	2 (P < 0	.00001)	; l² = 98	6%	-	-20 -10 0 10 20
Test for overall effect: Z = 3								Favou	rs [Spironolactonel] Favours [control]
Test for subaroup differen	ces: Chi ²	= 5.47.0	if = 3 (F	P = 0.14). I ² = 45	.2%		Favou	is tophonolacioned Pavou's [control]

Figure 4. Forest plots comparing the office SBP between the spironolactone group and other groups.

	Spire	onolactor	le	0	Control			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl
2.1.1 compared with pl	lacebo								
Ni et al., 2014	-11.5	11.67	40	0.5	10.64	36	13.8%	-12.00 [-17.02, -6.98]	
Oxlund et al., 2013	-9.7	12.8	61	-0.8	10.8	58	15.8%	-8.90 [-13.15, -4.65]	
Václavik et al., 2014	-12.6	12.6	74	-2.1	13.2	76	16.2%	-10.50 [-14.63, -6.37]	
Subtotal (95% CI)			175			170	45.7%	-10.31 [-12.86, -7.76]	•
Heterogeneity: Tau ² = 0	.00; Chi2	= 0.87, df	= 2 (P	= 0.65)	; I ² = 0%	6			
Test for overall effect: Z	= 7.93 (P	< 0.0000	11)						
2.1.2 compared with a	Iternative	drugs							
Bobrie et al., 2012	-17	16	85	-7	15	82	14.6%	-10.00 [-14.70, -5.30]	
Krieger EM et al. 2018	-12	13.16	84	-7.8	13.33	78	16.3%	-4.20 [-8.28, -0.12]	
Subtotal (95% CI)			169			160	30.9%	-6.98 [-12.66, -1.30]	-
Heterogeneity: Tau ² = 1	1.77; Chi	= 3.33, 0	df = 1 (P = 0.07	7); 2 = 7	0%			
Test for overall effect: Z	= 2.41 (P	= 0.02)							
2.1.3 compared with R	DN								
Oliveras A et al. 2016	-23.6	15.268	13	-5.7	15.4	11	4.2%	-17.90 [-30.22, -5.58]	
Rosa J et al. 2016	-8.2	17.4	50	-6.4	13.16	51	11.5%	-1.80 [-7.83, 4.23]	
Subtotal (95% CI)			63			62	15.6%	-8.92 [-24.59, 6.75]	
Heterogeneity: Tau ² = 1	05.13; CH	ni² = 5.30,	df = 1	(P = 0.0)	02); I ² =	81%			
Test for overall effect: Z	= 1.12 (P	= 0.26)							
2.1.4 compared with b	lank								
Yang L et al. 2016	-16.3	10.15	15	-5.3	12.75	15	7.8%	-11.00 [-19.25, -2.75]	
Subtotal (95% CI)			15			15	7.8%	-11.00 [-19.25, -2.75]	
Heterogeneity: Not app	licable								
Test for overall effect: Z	= 2.61 (P	= 0.009)							
Total (95% CI)			422			407	100.0%	-8.71 [-11.46, -5.95]	•
Heterogeneity: Tau ² = 7	.81; Chi ²	= 14.80, 0	df = 7 (P = 0.04	4); I ² = 5	3%			-20 -10 0 10 20
		< 0.0000							

Figure 5. Forest plots comparing the 24-hour ambulatory SBP between the spironolactone group and other groups.

	Spire	onolacto	one	p	lacebo			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% C	IV, Random, 95% CI
1.2.1 compared with place	ebo								
Abolghasmi et al., 2011	-12	3	19	-2	5	22	9.6%	-10.00 [-12.49, -7.51]	· · ·
Ni et al., 2014	-9	12.67	40	-1	13.43	36	6.5%	-8.00 [-13.89, -2.11]	
Oxlund et al., 2013	-5.7	8	61	1.1	7.9	58	9.3%	-6.80 [-9.66, -3.94]	
Rossignol P et al. 2018	-7.47	11.91	164	-4.33	12	174	9.5%	-3.14 [-5.69, -0.59]	
Václavik et al., 2014	-7.4	13.4	74	-4.4	9.1	76	8.5%	-3.00 [-6.68, 0.68]	
Williams et al., 2015	-10.3	11.2	285	-6.1	10.6	274	10.1%	-4.20 [-6.01, -2.39]	
Subtotal (95% CI)			643			640	53.3%	-5.73 [-8.13, -3.33]	•
Heterogeneity: Tau ² = 6.43	3; Chi ² =	21.12, 0	df = 5 (F	P = 0.00	08); I ² =	76%			
Test for overall effect: Z =	4.68 (P =	0.0000	11)						
1.2.2 compared with alte	rnative d	frugs							
Bobrie et al., 2012	-11	10.1	85	-8	11	82	8.9%	-3.00 [-6.21, 0.21]	
Djoumessi et al. 2016	-14	9.8	9	-5	10.5	8	3.9%	-9.00 [-18.69, 0.69]	
Krieger EM et al. 2018	-19.3	12.04	84	-22.1	13.6	78	8.2%	2.80 [-1.17, 6.77]	
Williams et al., 2015	-10.3	11.2	285	-11.5	11.2	285	10.0%	1.20 [-0.64, 3.04]	i +
Subtotal (95% CI)			463			453	31.1%	-0.56 [-3.92, 2.79]	•
Heterogeneity: Tau ² = 7.33	2; Chi ² =	10.05, 0	df = 3 (F	P = 0.02); $I^2 = 70$)%			
Test for overall effect: Z =	0.33 (P =	0.74)							
1.2.3 compared with RDN	1								
Oliveras A et al. 2016	-12.7	13.34	13	-7.5	13.54	11	3.3%	-5.20 [-16.00, 5.60]	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Rosa J et al. 2016	-6.2	12.44	50	-8.4	15.13	51	6.9%	2.20 [-3.20, 7.60]	i <u>+</u>
Subtotal (95% CI)			63			62	10.2%	0.04 [-6.56, 6.63]	
Heterogeneity: Tau ² = 8.4	1; Chi ² =	1.44, df	= 1 (P	= 0.23);	I= 319	8			
Test for overall effect: Z =	0.01 (P =	0.99)							
1.2.4 compared with blan	ık								
Yang L et al. 2016	-5.7	10.67	15	-2.4	9.55	15	5.4%	-3.30 [-10.55, 3.95]	
Subtotal (95% CI)			15			15	5.4%	-3.30 [-10.55, 3.95]	
Heterogeneity: Not applica	able								
Test for overall effect: Z =	0.89 (P =	: 0.37)							
Total (95% CI)			1184			1170	100.0%	-3.54 [-5.92, -1.16]	• • •
Heterogeneity: Tau ² = 13.	80; Chi ² :	= 74.64.	df = 12	2 (P < 0.	00001);	² = 84	%		-20 -10 0 10 2
Test for overall effect: Z = :				12.1	1				
Test for subaroup differen				(P = 0.0))6) I ² =	59.2%			Favours [experimental] Favours [control]

Figure 6. Forest plots comparing the office DBP between the spironolactone group and other groups.

	Spiro	nolacte	one	C	ontrol			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl
2.2.1 compared with pl	acebo								
Ni et al., 2014	-7.5	10.11	40	-1.5	12.28	36	8.8%	-6.00 [-11.09, -0.91]	
Oxlund et al., 2013	-4.2	6.2	61	-0.3	6.1	58	17.3%	-3.90 [-6.11, -1.69]	-
Václavik et al., 2014	-5.5	7.6	74	-2	7.8	76	16.4%	-3.50 [-5.96, -1.04]	
Subtotal (95% CI)			175			170	42.4%	-3.94 [-5.50, -2.37]	•
Heterogeneity: Tau ² = 0	.00; Chi*	= 0.75,	df = 2 (P = 0.69); I ^z = 0	%			
Test for overall effect: Z	= 4.93 (P	< 0.00	001)						
2.2.2 compared with al	ternative	drugs							
Bobrie et al., 2012	-10	10.5	85	-6	10	82	14.1%	-4.00 [-7.11, -0.89]	
Krieger EM et al. 2018	-6.3	10	84	-4.2	9.8	78	14.3%	-2.10 [-5.15, 0.95]	
Subtotal (95% CI)			169			160	28.5%	-3.03 [-5.21, -0.85]	•
Heterogeneity: Tau ² = 0	.00; Chi ²	= 0.73,	df = 1 (P = 0.39); I ² = 0	%			
Test for overall effect: Z	= 2.73 (P	= 0.00	6)						
2.2.3 compared with R	DN								
Oliveras A et al. 2016	-10.2	7.6	13	-3.7	7.69	11	6.9%	-6.50 [-12.64, -0.36]	
Rosa J et al. 2016	-6	9.85	50	-5.6	7.99	51	12.9%	-0.40 [-3.90, 3.10]	
Subtotal (95% CI)			63			62	19.7%	-2.91 [-8.79, 2.98]	-
Heterogeneity: Tau ² = 1	2.10; Chi	= 2.88	i, df = 1	(P = 0.0)	9); I ² =	65%			
Test for overall effect: Z	= 0.97 (P	= 0.33)						
2.2.4 compared with bl	lank								
Yang L et al. 2016	-14.9	7.8	15	-2.9	5.3	15		-12.00 [-16.77, -7.23]	
Subtotal (95% CI)			15			15	9.4%	-12.00 [-16.77, -7.23]	•
Heterogeneity: Not appl	licable								
Test for overall effect: Z	= 4.93 (P	< 0.00	001)						
Total (95% CI)			422			407	100.0%	-4.27 [-6.20, -2.34]	•
Heterogeneity: Tau ² = 4	.36; Chi*	= 17.69	, df = 7	(P = 0.0))1); I ^z =	60%			-20 -10 0 10 20
Test for overall effect: Z	= 4.33 (P	< 0.00	01)						-20 -10 0 10 20 wours [Spironolactone] Favours [control]
Test for subaroup differ	oncos C	$hi^2 - 11$	65 df	- 2/P -	0.000	12-74	296	Fa	wours [spironolacione] Favours [control]

Figure 7. Forest plots comparing the 24-hour ambulatory DBP between the spironolactone group and other groups.

	Spiro	nolactor	1e	(Control			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% C	IV, Random, 95% Cl
3.1.1 Time< 3 months									
Abolghasmi et al., 2011	-33	8	19	-2	10	22	12.4%	-31.00 [-36.51, -25.49]	
Václavik et al., 2014	-17.6	15.5	74	-7.7	14.4	76	12.5%	-9.90 [-14.69, -5.11]	
Subtotal (95% CI)			93			98	25.0%	-20.40 [-41.08, 0.27]	
Heterogeneity: Tau ² = 215.66;	Chi ² = 32	.06, df =	1 (P < 0	0.00001); I ² = 97	%			
Test for overall effect: Z = 1.93	(P = 0.05))							
3.1.2 Time= 3 months									
Abolghasmi et al., 2011	-36	10	19	5	10	22	12.3%	-41.00 [-47.14, -34.86]	
Ni et al., 2014	-20	11.63	40	-3	15.4	36	12.3%	-17.00 [-23.19, -10.81]	
Williams et al., 2015	-20.7	18.5	285	10.8	18.2	274	12.8%	-31.50 [-34.54, -28.46]	-
Subtotal (95% CI)			344			332	37.4%	-29.88 [-41.13, -18.64]	-
Heterogeneity: Tau ² = 91.47; C	hi ² = 29.9	1, df = 2	(P < 0.	00001);	= 939	\$6			
Test for overall effect: Z = 5.21	(P < 0.00	001)							
3.1.3 Time> 3 months									
Oxlund et al., 2013	-10.5	15.618	61	5.3	17.4	58	12.3%	-15.80 [-21.75, -9.85]	
Rossignol P et al. 2018	-15.65	19.47	164	-9.82	19.52	174	12.6%	-5.83 [-9.99, -1.67]	·
Rossignol P 16weeks. 2018	-15.07	18.55	173	-9.54	18.48	193	12.7%	-5.53 [-9.33, -1.73]	
Subtotal (95% CI)			398			425	37.7%	-8.62 [-14.23, -3.01]	•
Heterogeneity: Tau ² = 18.97; C	hi ² = 9.12	2, df = 2 (P = 0.0	1); I ² = 7	8%				
Test for overall effect: Z = 3.01	(P = 0.00	3)							
Total (95% CI)			835			855	100.0%	-19.64 [-29.10, -10.17]	•
Heterogeneity: Tau ² = 180.07;	Chi ² = 23	4.47, df=	7 (P <	0.0000	1); I ² = 9	97%			-20 -10 0 10 20
Test for overall effect: Z = 4.06	(P < 0.00	01)							
Test for subaroup differences:	Chi ² = 11	.48. df=	2 (P=	0.003).	= 82.6	%			Favours [experimental] Favours [control]
Fig	iure 8. F	Forest n	lot of	SBP in	subar	oup ar	nalvsis di	efined by the duration	a of intervention.

times. When office BP readings fail to demonstrate differences, differences in BP may be detected by ABPM.^[25] In the current study, no such differences were noted by office BP, although there was a better antihypertensive effect for ABPM reduction in the spironolactone group compared with the alternative drug group.

This meta-analysis also included 2 trials (with 165 patients) that evaluated the effectiveness of spironolactone and RND. Subgroup meta-analysis showed that spironolactone had the same antihypertensive effect as RND. In renal RND, patients

undergo splanchnic sympathectomy for the treatment of severe hypertension. The excess risk associated with RH is importantly linked to the development of CKD, which is known to be a major cardiovascular risk factor. Several studies initially reported that this intervention substantially reduced the elevated BP of RH patients, but this conclusion has not been supported by the results of this meta-analysis. The antihypertensive efficacy and overall validity of RND did not show a difference compared with spironolactone. In addition, many Chinese people tend to reject

	Spiro	nolacto	one	0	ontrol			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% C	I IV, Random, 95% CI
3.2.1 Time< 3 months									
Abolghasmi et al., 2011	-13	2	19	-3	6	22	13.1%	-10.00 [-12.66, -7.34	ı —
Václavik et al., 2014	-7.4	13.4	74	-4.4	9.1	76	11.3%	-3.00 [-6.68, 0.68	i
Subtotal (95% CI)			93			98	24.5%	-6.62 [-13.48, 0.24	i 🔶
Heterogeneity: Tau ² = 21.82; C	chi ² = 9.1	4, df = 1	(P = 0)	.003); 12	= 89%				
Test for overall effect: Z = 1.89	(P = 0.00	6)							
3.2.2 Time= 3 months									
Abolghasmi et al., 2011	-12	3	19	-2	5	22	13.4%	-10.00 [-12.49, -7.51	1
Ni et al., 2014	-9	12.67	40	-1	13.43	36	7.8%	-8.00 [-13.89, -2.11	i ———
Williams et al., 2015	-10.3	11.2	285	-6.1	10.6	274	14.5%	-4.20 [-6.01, -2.39	i —
Subtotal (95% CI)			344			332	35.8%	-7.26 [-11.70, -2.81	i 🍝
Heterogeneity: Tau ² = 12.32; C	chi ² = 14.	01, df=	2 (P =	0.0009)	² = 86	%			
Test for overall effect: Z = 3.20	(P = 0.0)	01)							
3.2.3 Time> 3 months									
Oxlund et al., 2013	-5.7	8	61	1.1	7.9	58	12.8%	-6.80 [-9.66, -3.94	1 -
Rossignol P et al. 2018	-7.47	11.91	164	-4.33	12	174	13.3%	-3.14 [-5.69, -0.59	i ——
Rossignol P 16weeks. 2018	-6.54	11.57	173	-4.33	11.61	193	13.6%	-2.21 [-4.59, 0.17	i
Subtotal (95% CI)			398			425	39.8%	-3.95 [-6.59, -1.32	i 🍝
Heterogeneity: Tau ² = 3.67; Ch	ni ² = 6.21	. df = 2	(P = 0.0))4); ² =	68%				
Test for overall effect: Z = 2.94	(P = 0.00	03)							
Total (95% CI)			835			855	100.0%	-5.82 [-8.12, -3.52	•
Heterogeneity: Tau ² = 8.62; Ch	ni ² = 39.4	2, df = 7	(P < 0	.00001)	I ² = 82	%			
Test for overall effect: Z = 4.97									-20 -10 0 10 2
Test for subgroup differences:			2 /P -	0.40) B	- 0%				Favours [experimental] Favours [control]


Figure 9. Forest plot of DBP in subgroup analysis defined by the duration of intervention.


	Spiro	nolacte	one	C	ontrol			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% C	IV, Random, 95% Cl
4.1.1 compared with play	cebo								
Abolghasmi et al., 2011	0.3	0.69	19	0.3	0.53	22	11.3%	0.00 [-0.38, 0.38	3]
Ni et al., 2014	0.3	1.3	40	0.2	1.23	36	8.2%	0.10 [-0.47, 0.67	7]
Oxlund et al., 2013	0.26	0.58	61	0.02	0.32	58	14.9%	0.24 [0.07, 0.41	j <u> </u>
Václavik et al., 2014	0.4	3.23	74	0	2.37	76	4.6%	0.40 [-0.51, 1.31	j
Subtotal (95% CI)			194			192	39.0%	0.20 [0.05, 0.35	•
Heterogeneity: Tau ² = 0.0	0; Chi ² =	1.58, d	f= 3 (P	= 0.66)	$ ^{2} = 0$	%			• (10)
Test for overall effect: Z =									
4.1.2 compared with alte	ernative d	Irugs							
Bobrie et al., 2012	0.3	0.71	85	0	1.15	82	12.9%	0.30 [0.01, 0.59	9]
Krieger EM et al. 2018	-0.2	2.17	95		2.13	92	7.5%	-0.20 [-0.82, 0.42	
Subtotal (95% CI)			180			174	20.5%	0.13 [-0.34, 0.59	
Heterogeneity: Tau ² = 0.0 Test for overall effect: Z =			lf=1 (P	= 0.15)); I ² = 5	2%			
restion overall ellect. Z =	0.05 (F -	0.59)							
4.1.3 compared with RDI	N								
Oliveras A et al. 2016	0.81	0.36	13	-0.13	0.39	11	12.7%	0.94 [0.64, 1.24	4)
Rosa J et al. 2016	0.04	0.53	50	0.08	0.71	51	13.7%	-0.04 [-0.28, 0.20	0]
Subtotal (95% CI)			63			62	26.4%	0.45 [-0.51, 1.41	
Heterogeneity: Tau ² = 0.4	6; Chi ² =	24.44,	df = 1 (P < 0.0	0001);	I= 96	%		
Test for overall effect: Z =	0.91 (P =	0.36)							
4.1.4 compared with bla	nk group								
Yang L et al. 2016	0	0.26	15	0.1	0.36	15	14.1%	-0.10 [-0.32, 0.12	2]
Subtotal (95% CI)			15			15	14.1%	-0.10 [-0.32, 0.12	
Heterogeneity: Not applic	able								
Test for overall effect: Z =	0.87 (P =	0.38)							
Total (95% CI)			452			443	100.0%	0.19 [-0.05, 0.42	
Heterogeneity: Tau ² = 0.0	9; Chi ² =	37.12,	df = 8 (P < 0.0	001); P	= 78%	,		-1 -0.5 0 0.5 1
Test for overall effect: Z =									
Test for subaroup differen			7 df - 1	P = 0	15) 12	- 42 10	×		Favours [experimental] Favours [control]

Figure 10. Forest plots comparing the serum potassium levels between the spironolactone group and other groups.

invasive treatment strategies.^[26] Based on our results, spironolactone had a better antihypertensive effect than other drugs, and its effects were not worse than those of RND, making it more suitable for many Chinese individuals.

Our study showed a significant benefit of spironolactone use in lowering BP in patients with RH, and the most frequent adverse events, such as hyperkalemia and gynecomastia/mastodynia, should be considered.^[27] Our subgroup meta-analysis showed that spironolactone significantly increased the concentration of





serum potassium compared with placebo. When compared with the other interventions, there was no significant difference in the serum potassium concentration with the use of spironolactone. The mild degree of the elevation of serum potassium with the administration of spironolactone may indicate the safety of the intervention. Although we did not have direct data to assess the incidence of adverse events, hyperkalemia still occurred in ~3% of patients receiving spironolactone in another study.^[28] Therefore, it is necessary to pay attention to serious adverse events caused by spironolactone.

4.1. Limitations

Several limitations of this study should be mentioned. First, unexplained high heterogeneity might affect the results of the subgroup meta-analysis, although we used strict inclusion criteria to ensure the inclusion of high-quality RCTs. Second, we

Table 2

Meta-regression and	alysis of potential	sources of	heterogeneity.
---------------------	---------------------	------------	----------------

Heterogeneity factor	Coefficient	SE	Z	<i>P</i> value	95% Cl (lower limit, upper limit)
Country	-0.9669	1.262643	-0.77	.486	-4.472584, 2.538732
Yr	1.2251	0.717655	1.71	.163	-0.7673576, 3.217702
Sample size	0.0515229	0.0347824	1.48	.213	-0.0450485, 0.1480943
Cutoff value	-2480.521	1445.197	-1.72	.161	-6493.032, 1531.989

CI = confidence interval.

			Quality assessment	ent			No of I	No of patients		Effect		
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Office BP	Control	Relative (95% CI)	Absolute	Quality	Importance
Office SBP												
12	Randomized	No serious risk	Very serious	No serious	No serious	None	1184	1170	I	MD 13.15 lower (20.79-5.51 lower)	$00 \oplus \oplus$	Important
	trials	of bias		indirectness	imprecision						Low	
Office SBP	- compared with	Office SBP - compared with placebo (subgroup analysis)	analysis)									
9	Randomized	No serious risk	Very serious	No serious	No serious	None	643	640	I	MD 20.14 lower (31.17-9.12 lower)	00⊕⊕	Critical
	trials	of bias		indirectness	imprecision						Low	
Office SBP	- compared with	Office SBP - compared with altemative drugs (subgroup analysis)	ubgroup analysis)									
4	Randomized	No serious risk	Very serious	No serious	No serious	None	463	453	Ι	MD 6.08 lower (12.83 lower to 0.68 higher)	00⊕⊕	Critical
	trials	of bias		indirectness	imprecision						Low	
Office SBP	- compared with	Office SBP - compared with RDN (subgroup analysis)	alysis)									
2	Randomized	No serious risk	Serious	No serious	No serious	None	63	62	Ι	MD 2.87 lower (16 lower to 10.26 higher)	O⊕⊕⊕	Critical
	trials	of bias		indirectness	imprecision						Moderate	
Office SBP	- compared with	Office SBP - compared with blank group (subgroup analysis)	oup analysis)									
, -	Randomized	No serious risk	No serious	No serious	No serious	None	15	15	I	MD 9 lower (16.85-1.15 lower)	$\oplus \oplus \oplus \oplus$	Not important
	trials	of bias	inconsistency	indirectness	imprecision						High	
Office DBP												
12	Randomized	No serious risk	Very serious	No serious	No serious	None	1184	1170	I	MD 3.54 lower (5.92-1.16 lower)	00⊕⊕	Important
	trials	of bias		indirectness	imprecision						Low	
Office DBP	- compared with	Office DBP - compared with placebo (subgroup analysis)	analysis)									
9	Randomized	No serious risk	Very serious	No serious	No serious	None	643	640	I	MD 5.73 lower (8.13-3.33 lower)	00⊕⊕	Critical
	trials	of bias		indirectness	imprecision						Low	
Office DBP	- compared with	Office DBP - compared with altemative drugs (subgroup analysis)	subgroup analysis)									
4	Randomized	No serious risk	Very serious	No serious	No serious	None	463	453	I	MD 0.56 lower (3.92 lower to 2.79 higher)	00⊕⊕	Critical
	trials	of bias		indirectness	imprecision						Low	
Office DBP	- compared with	Office DBP - compared with RDN (subgroup analysis)	alysis)									
2	Randomized	No serious risk	No serious	No serious	No serious	None	63	62	I	MD 0.04 higher (6.56 lower to 6.63 higher)	$\oplus \oplus \oplus \oplus$	Critical
	trials	of bias	inconsistency	indirectness	imprecision						High	
Office DBP	- compared with	Office DBP - compared with blank (subgroup analysis)	nalysis)									
. 	Randomized	No serious risk	No serious	No serious	No serious	None	15	15	I	MD 3.3 lower (10.55 lower to 3.95 higher)	$\oplus \oplus \oplus \oplus$	Not important
	trials	of hias	inconcictancy	indirantnaco	imnranieinn						Hinh	

Chen et al. Medicine (2020) 99:34

Medicine

Seign Risk of bias Inconsistency Indirectness Indirectness - compared with placebo (subgroup analysis) Randomized trials No serious Serious No serious		0	Quality assessment	int			No of	No of patients		Effect		
Sign Design Risk of bias Inconsistency Indirectness Imprecision ABP Control Fandomiced trials No serious Serious Serious No serious No serious AD 2010 422 407 - compared with placebo (subgroup analysis) - compared with alternative durits No serious No serious No serious None 422 407 - compared with alternative durits No serious No serious No serious None 155 170 - compared with Blanck (ubgroup analysis) - compared with Blanck (ubgroup analysis) No serious None 169 160 - compared with Blanck (subgroup analysis) - compared with Blanck (ubgroup analysis) No serious None 155 15 - compared with Blanck (subgroup analysis) - compared with Blanck (subgroup analysis) No serious No serious None 155 15 - compared with Blanck (subgroup analysis) - compared with Blanck (subgroup analysis) No serious No serious None 155 15 - compared with Blanck (subgroup analysis)						Other		ĺ	Relative			
Randomiced trials No serious Serious No serious No serious No 407 - compared with placebo (subgroup analysis) - compared with placebo (subgroup analysis) No serious No serious No 407 175 170 - compared with placebo (subgroup analysis) risk of blass inconsistency indirectness imprecision 169 160 - compared with attemative drugs (subgroup analysis) No serious No serious No serious None 175 170 - compared with attemative drugs (subgroup analysis) No serious No serious No serious None 169 160 - compared with blank (subgroup analysis) No serious No serious No serious None 15 15 - compared with blank (subgroup analysis) No serious No serious None 15 15 Randomiced trials No serious No serious No serious None 15 15 Randomiced trials No serious No serious No serious No serious None 15 170	Design		Inconsistency	Indirectness	Imprecision	considerations	ABP	Control	(02% CI)	Absolute	Quality	Importance
Is No serious No serious No serious No serious More etal Rindirectness imprecision None 175 170 Rindirectness imprecision None 169 160 Rindirectness imprecision None 169 160 Rindirectness imprecision None 15 170 Rindirectness imprecision None 169 160 Rindirectness imprecision None 15 15 Rindirectness imprecision None 15 15 Rindirectness imprecision None 15 15 Rindirectness imprecision None 15 170 Rindirectness imprecision None 15 170 Rindirectness imprecision None 15 170 Rindirectness imprecision None 169 160 Rindirectness imprecision None 15 15												
- compared with placeto (subgroup analysis) indirectness imprecision 175 170 - compared with placeto (subgroup analysis) No serious 175 170 - compared with placeto (subgroup analysis) - compared with alternative drugs (subgroup analysis) No serious No serious No serious No serious None 159 160 - compared with blank (subgroup analysis) - compared with blank (subgroup analysis) None 169 160 - compared with blank (subgroup analysis) - compared with blank (subgroup analysis) No serious No serious None 15 15 - compared with blank (subgroup analysis) - compared with blank (subgroup analysis) No serious No serious None 15 15 - compared with blank (subgroup analysis) - compared with blank (subgroup analysis) No serious No serious None 15 15 - compared with blank (subgroup analysis) - compared with blank (subgroup analysis) No serious No serious No serious None 15 15 - compared with blank (subgroup analysis) - compared with blank (subgroup analysis) No serious No serious No serious 175		serious	Serious	No serious	No serious	None	422	407	I	MD 8.71 lower (11.46-5.95 lower)	$0 \oplus \oplus \oplus$	Critical
 - compared with placebo (subgroup analysis) - compared with alternative drugs (subgroup analysis) - compared with alternative drugs (subgroup analysis) - compared with RDN (subgroup analysis) - compared with Bank (subgroup analysis) - compared with blank (subgroup analysis) - compared with placebo (subgroup analysis) - compared with Blank (subgroup	risk	k of bias		indirectness	imprecision						Moderate	
Randomized trials No serious No serious No serious No serious No 175 170 -compared with alternative drugs (ubgroup analysis) risk of blass inconsistency indirectness inprecision 169 160 -compared with alternative drugs (ubgroup analysis) -compared with alternative drugs (ubgroup analysis) No serious Very serious No serious Very serious 169 160 -compared with RDN (subgroup analysis) -compared with Diank (subgroup analysis) No serious No serious No 175 170 -compared with Diank (subgroup analysis) -compared with Diank (subgroup analysis) No serious No serious No 160 15 15 -compared with Diank (subgroup analysis) No serious No serious No serious None 15 17 Randomized trials No serious No serious No serious None 15 17 Randomized trials No serious No serious None 12 17 Randomized trials No serious No serious No serious	compared with placebo (subgru	roup analysis)										
risk of blas inconsistency indirectness imprecision - compared with alternative drugs (subgroup analysis) Randomized trials No serious Very serious No serious Very serious No serious 169 160 - compared with alternative drugs (subgroup analysis) - compared with RDN (subgroup analysis) No serious No serious No serious No serious No 169 160 - compared with Blank (subgroup analysis) - compared with Blank (subgroup analysis) No serious No serious No serious No serious No 169 160 - compared with Blank (subgroup analysis) - compared with Blank (subgroup analysis) No serious No serious No serious No serious No 175 170 - compared with Place (subgroup analysis) - compared with Place (blas No serious No serious None 125 170 - compared with Place (blas No serious No serious No serious No serious None 175 170 - compared with Place (blas No serious No serious No serious No serious None 175 170 - compared with Place (bl		serious	No serious	No serious	No serious	None	175	170	I	MD 10.31 lower (12.86-7.76 lower)	$\oplus \oplus \oplus \oplus$	Critical
 - compared with alternative drugs (subgroup analysis) - compared with RDN (subgroup analysis) - compared with BDN (subgroup analysis) - compared with BDN (subgroup analysis) - compared with blank (subgroup analysis) - compared with alternative drugs (subgroup analysis) - compared with blank (subgroup analysis)<	risk	c of bias	inconsistency	indirectness	imprecision						High	
Randomized trials No serious Very serious No serious No serious 160 160 - compared with RDN (subgroup analysis) risk of blas No serious No serious No serious No 63 62 Randomized trials No serious Very serious No serious No serious None 63 62 Randomized trials No serious No serious No serious None 15 15 Randomized trials No serious No serious No serious None 15 15 Randomized trials No serious No serious No serious None 15 15 Randomized trials No serious No serious No serious None 175 170 Randomized trials No serious No serious No serious No serious None 175 170 Randomized trials No serious No serious No serious No serious None 175 170 Randomized trials No serious No serious No serious No serious None 175 170	compared with alternative drug	gs (subgroup	analysis)									
risk of bias indirectness imprecision - compared with RDN (subgroup analysis) Ne serious No serious No serious No serious None 63 62 - compared with blank (subgroup analysis) risk of bias No serious No serious No serious No serious None 63 62 - compared with blank (subgroup analysis) No serious No serious No serious No serious None 15 15 Randomized trials No serious No serious No serious No serious None 407 Randomized trials No serious No serious No serious None 15 170 Randomized trials No serious No serious None 422 407 Randomized trials No serious No serious None 175 170 Randomized trials No serious No serious None 175 170 Randomized trials No serious No serious None 169 160 Randomized trials No serious No serious None 175 170 <t< td=""><td></td><td>serious</td><td>Very serious</td><td>No serious</td><td>No serious</td><td>None</td><td>169</td><td>160</td><td>I</td><td>MD 6.98 lower (12.66-1.3 lower)</td><td>00⊕⊕</td><td>Critical</td></t<>		serious	Very serious	No serious	No serious	None	169	160	I	MD 6.98 lower (12.66-1.3 lower)	00⊕⊕	Critical
 - compared with RDN (subgroup analysis) - compared with RDN (subgroup analysis) - risk of bias - compared with blank (subgroup analysis) - risk of bias - nconsistency - nconserious - nconsistency	risk	t of bias		indirectness	imprecision						Low	
Randomized trialsNo seriousVery seriousNo seriousNo seriousNo seriousNo seriousNo seriousNoSeriousSeriousSeriousNoSeriousSeriousNoSeriousSeriousNoSeriousNoSeriousSeriousNoSeriousSeriousNoSeriousNoSeriousSeriousNoSeriousN	compared with RDN (subgroup	o analysis)										
risk of bias indirectness imprecision - compared with blank (subgroup analysis) No serious No serious No serious No serious No serious No serious None 15 15 Randomized trials No serious No serious No serious No serious None 15 15 Randomized trials No serious No serious No serious No serious None 422 407 - compared with placebo (subgroup analysis) - compared with alternative drug (subgroup analysis) - non serious No serious None 175 170 - compared with alternative drug (subgroup analysis) - compared with alternative drug (subgroup analysis) - non serious No serious None 175 170 - compared with alternative drug (subgroup analysis) - compared with alternative drug (subgroup analysis) - non serious No serious None 175 170 - compared with Blank (subgroup analysis) - compared with blank (subgroup analysis) - compared with blank (subgroup analysis) </td <td></td> <td>serious</td> <td>Very serious</td> <td>No serious</td> <td>No serious</td> <td>None</td> <td>63</td> <td>62</td> <td>I</td> <td>MD 8.92 lower (24.59 lower to 6.75 higher)</td> <td>00⊕⊕</td> <td>Critical</td>		serious	Very serious	No serious	No serious	None	63	62	I	MD 8.92 lower (24.59 lower to 6.75 higher)	00⊕⊕	Critical
 - compared with blank (subgroup analysis) - Randomized trials No serious isk of blas inconsistency indirectness imprecision - Randomized trials No serious inconsistency indirectness imprecision - compared with placebo (subgroup analysis) - compared with alternative drugs (subgroup analysis) - compared with alternative drugs (subgroup analysis) - compared with alternative drugs (subgroup analysis) - compared with blank (subgroup analysis) 	risk	t of bias		indirectness	imprecision						Low	
Randomized trials No serious No serious No serious No serious No serious 15 15 Randomized trials No serious No serious No serious None 15 15 - compared with placebo (subgroup analysis) - compared with placebo (subgroup analysis) No serious No serious No serious None 422 407 - compared with placebo (subgroup analysis) - compared with atternative drugs (subgroup analysis) No serious No serious No serious None 175 170 - compared with atternative drugs (subgroup analysis) - compared with atternative drugs (subgroup analysis) No serious No serious No serious None 175 170 - compared with RDN (Subgroup analysis) - compared with RDN (Subgroup analysis) No serious No serious No serious No serious None 169 160 - compared with BDN (Subgroup analysis) - compared with BDN (Subgroup analysis) No serious No serious No serious No serious None 169 160 - compared with BDN (Subgroup analysis) - compared with BDN (Subgroup analysis) - compared with BDN (Subgroup analysis) - compared with	compared with blank (subgrout	up analysis)										
risk of bias inconsistency indirectness imprecision Randomized trials No serious Serious No serious No serious None 422 407 risk of bias risk of bias indirectness imprecision Randomized trials No serious No serious No serious No serious None 175 170 - compared with alternative drugs (subgroup analysis) - compared with alternative drugs (subgroup analysis) Randomized trials No serious No serious No serious None 175 170 - compared with alternative drugs (subgroup analysis) - compared with RDN (Subgroup analysis) - compared with RDN (Subgroup analysis) - compared with blank (subgroup analysis)		serious	No serious	No serious	No serious	None	15	15	I	MD 11 lower (19.25-2.75 lower)	$\oplus \oplus \oplus \oplus$	Not important
Randomized trials No serious Serious No serious No serious 407 - compared with placebo (subgroup analysis) - risk of bias - indirectness indirectness inprecision 422 407 - compared with placebo (subgroup analysis) - compared with placebo (subgroup analysis) No serious No serious No serious No serious 175 170 - compared with alternative drugs (subgroup analysis) - compared with alternative drugs (subgroup analysis) No serious No serious No serious None 169 160 - compared with alternative drugs (subgroup analysis) - compared with alternative drugs (subgroup analysis) None 169 160 - compared with RDN (Subgroup analysis) - compared with Bank (subgroup analysis) No serious No serious None 169 160 - compared with blank (subgroup analysis) - compared with blank (subgroup analysis) No serious No serious None 15 15 - compared with blank (subgroup analysis) - compared with blank (subgroup analysis) No serious No serious None 15 15 - compared with blank (subgroup analysis) - compared with blank (subgroup analysis)	risk	t of bias	inconsistency	indirectness	imprecision						High	
Is No serious No serious No serious 407 indirectness imprecision 422 407 ous No serious No serious None 175 170 ency indirectness imprecision None 175 170 ous No serious No serious None 169 160 ency indirectness imprecision None 63 62 indirectness imprecision None 15 15 ous No serious No serious None 15 15												
indirectness imprecision aus No serious No serious None 175 170 ency indirectness imprecision and indirectness imprecision Is No serious No serious None 63 62 indirectness imprecision ous No serious No serious None 15 15 indirectness imprecision		serious	Serious	No serious	No serious	None	422	407	I	MD 4.27 lower (6.2-2.34 lower)	$0 \oplus \oplus \oplus$	Critical
ous No serious No serious None 175 170 ency indirectness imprecision 015 169 160 ency indirectness imprecision None 169 160 and indirectness imprecision 015 15 15 ency indirectness imprecision 15 15	risk	<pre>< of bias</pre>		indirectness	imprecision						Moderate	
ous No serious No serious None 175 170 ency indirectness imprecision None 169 160 ency indirectness imprecision None 63 62 indirectness imprecision None 63 62 ous No serious No serious None 15 15 indirectness imprecision	compared with placebo (subgr-	roup analysis)	(
ency indirectness imprecision ous No serious No serious None 169 160 ency indirectness imprecision us No serious No serious None 63 62 undirectness imprecision ous No serious No serious None 15 15	Randomized trials No	serious		No serious	No serious	None	175	170	I	MD 3.94 lower (5.5-2.37 lower)	$\oplus \oplus \oplus \oplus$	Critical
ous No serious No serious None 169 160 ency indirectness imprecision Some 63 62 indirectness imprecision None 63 75 ous No serious No serious None 15 15 ency indirectness immercision	risk	<pre>< of bias</pre>	inconsistency	indirectness	imprecision						High	
No serious No serious No serious None 169 160 inconsistency indirectness imprecision Serious No serious None 63 62 indirectness imprecision No serious No serious None 15 15 inconsistency indirectness immerision	compared with alternative druc	igs (subgroup	analysis)									
inconsistency indirectness imprecision Serious No serious None 63 62 indirectness imprecision No serious No serious None 15 15 inconsistency indirectness immersion		serious	No serious	No serious	No serious	None	169	160	I	MD 3.03 lower (5.21-0.85 lower)	$\oplus \oplus \oplus \oplus$	Critical
SeriousNo seriousNo serious62indirectnessimprecision)No seriousNo serious1515inconsistencyindirectnessimmrecision	risk	c of bias	inconsistency	indirectness	imprecision						High	
Serious No serious No serious None 63 62 indirectness imprecision No serious No serious None 15 15 inconsistancy indirectness immodision	compared with RDN (Subgrouk	p analysis)										
indirectness imprecision No serious No serious None 15 15 inconsistancy indirectness immonision		serious	Serious	No serious	No serious	None	63	62	I	MD 2.91 lower (8.79 lower to 2.98 higher)	$0 \oplus \oplus \oplus$	Critical
No serious No serious No serious None 15 15 inconsistancy inclinactores immerision	risk	c of bias		indirectness	imprecision						Moderate	
No serious No serious No serious No serious None 15 15 risk of has inconsistency indirectness immerision	compared with blank (subgrou	up analysis)										
inconsistency indirectness		serious	No serious	No serious	No serious	None	15	15	I	MD 12 lower (16.77-7.23 lower)	$\oplus \oplus \oplus \oplus$	Not important
	risk	risk of bias	inconsistency	indirectness	imprecision						High	

www.md-journal.com

BP = blood pressure, Cl = confidence interval, MD = mean difference, RDN = renal denervation.

Table 4

included several trials with small sample sizes, which may have resulted in a risk of bias in this meta-analysis. Third, original data could not be accessed for every study, which might influence the results, although this is a limitation inherent to all study-level meta-analysis. Fourth, we did not evaluate the incidence of hyperkalemia due to a lack of data in multiple studies. In the future, the occurrence of other long-term complications in patients who use spironolactone should be analyzed. Fifth, the prevalence of primary aldosteronism (PA) is very high in RH patients. However, several studies did not evaluate the influence of spironolactone on PA. Therefore, we did not fully evaluate the safety of using spironolactone.

4.2. Future directions

The finding that a 3-month duration of spironolactone intervention had the best effect was newly discovered through our meta-analysis, but the specific mechanism is not clear. Our later research will further explore the specific mechanism of the drug to provide theoretical support for the clinical application of spironolactone.

5. Conclusion

This meta-analysis fully evaluated the antihypertensive effect of spironolactone compared with placebo, alternative drugs, RND and no treatment. Spironolactone can result in a substantial BP reduction in patients with RH at 3 months. Additionally, more large and long-term randomized controlled trials, including data that evaluate the incidence of hyperkalemia and long-term adverse events, are needed.

Author contributions

XXXX.

References

- Daugherty SL, Powers JD, Magid DJ, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation 2012; 125:1635–42.
- [2] Williams B. Resistant hypertension: an unmet treatment need. Lancet 2009;374:1396–8.
- [3] Sarafidis PA, Bakris GL. Resistant hypertension: an overview of evaluation and treatment. J Am Coll Cardiol 2008;52:1749–57.
- [4] Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013;34:2159–219.
- [5] James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014;311:507–20.
- [6] de Souza F, Muxfeldt E, Fiszman R, et al. Efficacy of spironolactone therapy in patients with true resistant hypertension. Hypertension 2010;55:147–52.
- [7] Guglin M, Kristof-Kuteyeva O, Novotorova I, et al. Aldosterone antagonists in heart failure. J Cardiovasc Pharmacol Ther 2011;16:150–9.

Medicine

- with treatment-resistant hypertension. Trends Cardiovasc Med 2016;26: 700–6.
- [9] Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009;339:b2535.
- [10] Ni X, Zhang J, Zhang P, et al. Effects of spironolactone on dialysis patients with refractory hypertension: a randomized controlled study. J Clin Hypertens (Greenwich) 2014;16:658–63.
- [11] Rossignol P, Claggett BL, Liu J, et al. Spironolactone and resistant hypertension in heart failure with preserved ejection fraction. Am J Hypertens 2018;31:407–14.
- [12] Yang L, Zhang H, Cai M, et al. Effect of spironolactone on patients with resistant hypertension and obstructive sleep apnea. Clin Exp Hypertens 2016;38:464–8.
- [13] Abolghasmi R, Taziki O. Efficacy of low dose spironolactone in chronic kidney disease with resistant hypertension. Saudi J Kidney Dis Transpl 2011;22:75–8.
- [14] Djoumessi RN, Noubiap JJ, Kaze FF, et al. Effect of low-dose spironolactone on resistant hypertension in type 2 diabetes mellitus: a randomized controlled trial in a sub-Saharan African population. BMC Res Notes 2016;9:187.
- [15] Oxlund CS, Henriksen JE, Tarnow L, et al. Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial. J Hypertens 2013;31:2094–102.
- [16] Oliveras A, Armario P, Clara A, et al. Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study - a randomized controlled trial. J Hypertens 2016;34:1863–71.
- [17] Rosa J, Widimsky P, Waldauf P, et al. Role of adding spironolactone and renal denervation in true resistant hypertension: one-year outcomes of randomized PRAGUE-15 study. Hypertension 2016;67: 397–403.
- [18] Bobrie G, Frank M, Azizi M, et al. Sequential nephron blockade versus sequential renin-angiotensin system blockade in resistant hypertension: a prospective, randomized, open blinded endpoint study. J Hypertens 2012;30:1656–64.
- [19] Krieger EM, Drager LF, Giorgi DMA, et al. Spironolactone versus clonidine as a fourth-drug therapy for resistant hypertension: the ReHOT randomized study (resistant hypertension optimal treatment). Hypertension 2018;71:681–90.
- [20] Manolis A, Manolis T, Melita H, et al. eplerenone versus spironolactone in resistant hypertension: an efficacy and/or cost or just a men's issue? Curr Hypertens Rep 2019;21:22.
- [21] Egan BM, Li J. Role of aldosterone blockade in resistant hypertension. Semin Nephrol 2014;34:273–84.
- [22] Buglioni A, Cannone V, Sangaralingham SJ, et al. Aldosterone predicts cardiovascular, renal, and metabolic disease in the general community: a 4-year follow-up. J Am Heart Assoc 2015;4:
- [23] Zhao D, Liu H, Dong P, et al. A meta-analysis of add-on use of spironolactone in patients with resistant hypertension. Int J Cardiol 2017;233:113-7.
- [24] Bakris GL, Townsend RR, Liu M, et al. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. J Am Coll Cardiol 2014;64:1071–8.
- [25] Weber M. Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial. Hypertension. 2010;56:824-30.
- [26] Morganti A, Mancia G. Resistant hypertension: renal denervation or intensified medical treatment? Eur J Intern Med 2018;50:6–11.
- [27] Colussi G, Catena C, Sechi LA. Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension. J Hypertens 2013;31:3–15.
- [28] Tataru AP, Barry AR. A Systematic review of add-on pharmacologic therapy in the treatment of resistant hypertension. Am J Cardiovasc Drugs 2017;17:311–8.